Impel NeuroPharma Inc. (IMPL) Launches 3M Share Proposed Offering

Impel Neuropharma (IMPL) PT Raised to $50 at Guggenheim

Guggenheim analyst Eddie Hickman raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $50.00 (from $32.00) while maintaining a Buy rating.

Impel Neuropharma (IMPL) PT Raised to $31 at Wedbush

Wedbush analyst Laura Chico raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $31.00 (from $25.00) while maintaining a Outperform rating.

Impel Neuropharma (IMPL) PT Raised to $55 at Cowen on FDA Approval

Cowen analyst Ken Cacciatore raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $55.00 (from $35.00) while maintaining an Outperform rating.

The analyst commented, "The FDA has approved Trudhesa for the treatment of acute migraines with a clean label right in line with our... More

Pre-Open Stock Movers 09/03: (APOP) (IMPL) (MDB) Higher; (FBRX) (YEXT) (JOAN) Lower (more...)

Pre-Open Stock Movers

Forte Biosciences, Inc. (NASDAQ: FBRX) 80.4% LOWER; announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI).

Cellect Biotechnology Ltd. (NASDAQ: APOP) 64% HIGHER; announced the first ApoGraftTM transplantation in a Leukemia patient in the... More

Impel NeuroPharma Inc. (IMPL) surges 59% as trading reumes on FDA approval

Impel NeuroPharma Inc. (NASDAQ: IMPL) surges 59% as trading reumes on FDA approval

Impel NeuroPharma Inc. (IMPL) Announces FDA Approval of TRUDHESA for Migraine

Impel NeuroPharma, Inc. (NASDAQ: IMPL) announced that the U.S. Food and Drug Administration (FDA) approved TRUDHESA (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. TRUDHESA was previously known as INP104.

Using Impels proprietary Precision Olfactory Delivery (POD®) technology, TRUDHESA gently delivers dihydroergotamine mesylate (DHE)a proven, well-established therapeuticquickly to the bloodstream through the vascular-rich upper nasal space.1 TRUDHESA bypasses the gut and potential absorption issues, offering rapid, sustained, and consistent symptom relief without injection or infusion,... More

Impel NeuroPharma Inc. (IMPL) halted, news pending

Impel NeuroPharma Inc. (NASDAQ: IMPL) halted, news pending